Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer

NCT03396211 is registered in ClinicalTrials.gov with Elevar Therapeutics as lead sponsor.

NCT NCT03396211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03396211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer
Lead sponsor
Elevar Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 22, 2017
Completion date
March 16, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer